Havas acquires India-based health agency Sorento

Agency will be integrated with Havas Health & You India to form Havas Life Sorento.

L-R: Sangeeta Barde, Susan Josi
L-R: Sangeeta Barde, Susan Josi

Havas Group has announced the acquisition of Sorento, an India-based healthcare-communications agency.

Following the acquisition, Sorento will integrate with Havas Health & You India and rebrand as Havas Life Sorento. Sorento's clients include international brands such as Abbott and Johnson & Johnson as well as local pharmas like Alkem and Dr Reddy's. 

The co-founders and managing partners of the agency, Susan Josi and Sangeeta Barde, will retain their roles and head the 70-person team. They will both report to Charles Houdoux, CEO, Havas Health & You APAC. The duo said in a statement that joining Havas opens up frontiers for the agency in India and beyond.

Donna Murphy, CEO, Havas Health & You, said in a statement: "The Sorento culture of innovative, best-in-class client service makes it an ideal fit for the Havas Health & You family. Its integrated approach to brand stewardship has resulted in long-term relationships with clients, which also aligns with our client-first philosophy.”

Source:
Campaign Asia

Related Articles

Just Published

11 hours ago

Omnicom cut 3,000 roles during 2024 ahead of IPG ...

Total headcount fell 1,000, as job reductions more than offset acquisition of 2000-strong Flywheel, and agency group plans further staff cuts to save US$330 million.

12 hours ago

40 Under 40 2024: Tala Booker, Via

What does it take to build a global communications agency in a year? Ask Tala Booker, the former HSBC executive who's rewriting the rules.

13 hours ago

Majority of marketers are unprepared to combat ...

A report from Forrester highlights the risks that companies face from deepfakes, as well as the current inadequate state of preparation to combat the problem.

14 hours ago

The unbearable cost of truth

As information retreats behind paywalls and attention splinters into subscription tiers, advertising faces its terminal paradox: We've made truth so expensive that soon, no one will be left who can afford to buy what we're selling.